Exclusive Interviews

To wrap up this series, we present the final two installments of the conversation between Diabetes in Control Publisher Steve Freed and Dr. Richard Bergman. In part 5, Steve learns more about the institute founded and led by Dr. Bergman at Cedars-Sinai. In part 6, Steve asks what is more important — blood pressure or blood glucose levels?

Diabetes in Control Publisher Steve Freed and Dr. Richard Bergman discuss his ADA presentations — the relationship between diabetes and altitude, and the role of kidneys in diabetes research. Steve also asks why the degredation of insulin in the liver is important in the pathogenesis of diabetes. Dr. Bergman is the founder and director of Diabetes and Obesity Research Institute, Biomedical Sciences at Cedars-Sinai in Los Angeles. He introduced the use of engineering principles to understand the pathogenesis of diabetes.

Diabetes in Control Publisher Steve Freed and Dr. Richard Bergman, founder and director of Diabetes and Obesity Research Institute, Biomedical Sciences at Cedars-Sinai in Los Angeles, discuss the ability to predict the development of type 2 diabetes and the role A1c might play in this prediction.

Diabetes in Control publisher Steve Freed and Dr. Richard Bergman discuss who is insulin resistant and the risk factors for insulin resistance. Dr. Richard Bergman is the founder and director of the Diabetes and Obesity Research Institute, Biomedical Sciences at Cedars-Sinai in Los Angeles. He introduced the use of engineering principles to understand the pathogenesis of diabetes. Dr. Bergman was awarded the Albert Renold Award at the American Diabetes Association's 75th Scientific Sessions in Boston for a career distinguished by outstanding achievements in the training and mentorship of diabetes research scientists, and in the facilitation of diabetes research.

Diabetes in Control Publisher Steve Freed meets with Dr. Richard Bergman at the 75th ADA Scientific Sessions in Boston. In this first installment, Dr. Bergman shares his start in diabetes research and explains the high points of his presentation, Comparative Methods for Assessment of Insulin Sensitivity: Oral Vs. Intravenous. Dr. Richard Bergman is the founder and director of Diabetes and Obesity Research Institute, Biomedical Sciences at Cedars-Sinai in Los Angeles. He introduced the use of engineering principles to understand the pathogenesis of diabetes.

Diabetes in Control publisher Steve Freed met with Dr. Larry Hirsch, Vice President of Global Medical Affairs for the Diabetes Care Business at BD at the 2015 ADA Sessions in Boston. In this final installment, Dr. Hirsch summarizes his ADA 2015 presentation, including a comparison of the BD infusion set to the current popular model, and images showing the fluid within infusion sets as captured by MRI and ultrasound.

Diabetes in Control publisher Steve Freed met with Dr. Larry Hirsch, Vice President of Global Medical Affairs for the Diabetes Care Business at BD at the 2015 ADA Sessions in Boston. This week, Dr. Hirsch discusses the unexplainable highs, known as silent occlusions, that some patients using pumps may experience.

Diabetes in Control publisher Steve Freed met with Dr. Larry Hirsch, Vice PresidLarry Hirschent of Global Medical Affairs for the Diabetes Care Business at BD at the 2015 ADA Sessions in Boston. This week, Dr. Hirsch shares the results of his investigation into infusion sets, the "achilles heel of pumps," which have rarely been the focus of past research. BD is working toward an innovative change to this common technology.

With multiple Top 10 finishes, veteran Team Novo Nordisk rider Martijn Verschool is back in the saddle this week as he prepares to compete in the Tour of Hainan.

Diabetes in Control publisher Steve Freed meets with Dr. Larry Hirsch, Vice President of Global Medical Affairs for the Diabetes Care Business at BD at the 2015 ADA Sessions in Boston. Dr. Hirsch talks about the work toward improving patient experience when taking injections and the results of a study on the nano needle use in obese patients.